Kilitch Drugs Q3 results with 1:1 bonus issue and capital hike

Revenue declinedResults View source PDF Explain this filing

KILITCH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-8.6%Reaction day

₹181.50

prior close

₹180.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%-8.1% vs market

Pharmaceuticals peers, median of 157sector-0.6%-8.0% vs sector

On the reaction day the stock moved 8.1 pts less than Nifty Microcap 250 and 8.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.1

10m

-1.8

15m

-2.5

30m

-3.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-8.6-0.5-8.1-0.6-8.0

Next day

-9.9-2.0-7.9-1.4-8.5

-12.1-2.7-9.4-2.1-10.0

-11.3-1.7-9.6-1.6-9.7

-8.8-1.4-7.4-1.6-7.2

-12.5-2.8-9.7-2.4-10.1

-10.5-2.8-7.6-2.9-7.6

15d

-11.6-8.4-3.2-6.3-5.2

-9.7-9.1-0.6-6.5-3.2

-31.6-4.0-27.5-3.3-28.2

-19.0+2.6-21.6+0.9-19.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Kilitch Drugs reported Q3 FY26 standalone net sales of Rs 44.67 cr with PAT of Rs 4.89 cr. 9M standalone revenue dipped to Rs 116.6 cr from Rs 125.3 cr. Board approved 1:1 bonus share issue, raising authorized capital from Rs 25 cr to Rs 40 cr. EGM on March 13 for shareholder nod. A Rs 49.92 cr rights issue was completed in Aug 2025 to fund the Pen Greenfield project.

Likely market impact

Bonus doubles share count, may pressure stock short-term. Revenue dip in 9M is a watch point.